Pills masthead

News Releases

Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014

201320122011201020092008200720062004

May 2, 2023

Restructuring Support Agreement Supported by Holders of More than 80% of the Company's Senior Secured Notes and 100% of Holders of Second Lien Term Loan Restructuring Transactions Will Reduce the...

More
May 1, 2023

Restructuring Support Agreement Supported by Holders of More Than 80% of the Company's Senior Secured Notes and 100% of the Company's Second Lien Term Loans Transaction Will Significantly...

More
Apr 20, 2023

Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett...

More
Apr 4, 2023

Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product Productive Conversations with Key Secured Creditors Toward a Balance Sheet...

More
Feb 1, 2023

Q2 Business and Financial Highlights: Net Sales were $80.9 Million Gross Margin was 18%, Adjusted Gross Margin was 19% Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two...

More
Jan 25, 2023

Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors approved a 1-for-4 reverse stock split of its issued and outstanding shares of common stock, effective at 5 p.m....

More
Jan 25, 2023

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett...

More
Jan 4, 2023

--Announces Positive Animal PK Study Results of Insulin Aspart Versus US NovoLogĀ®-- --Analysis of Pivotal Trial Results of Insulin Glargine Nearly Completed, BLA Filing Timeline Slightly Delayed,...

More
Nov 7, 2022

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its...

More
Nov 2, 2022

Q1 Business and Financial Highlights: Net Sales were $75.1 Million Gross Margin 17%, Adjusted Gross Margin 18% Net Sales, Gross Margin and Adjusted Gross Margin Increased from Preceding Quarter...

More
 
Price Data
NYSELCI